Nov 14, 2024, 15:58
Iván R. González: Warning on Sotorasib Treatment for Advanced Lung Cancer
Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared on X:
“Warning on Sotorasib Treatment for Advanced Lung Cancer.
Sotorasib, the first RAS inhibitor approved for KRASG12C-mutated NSCLC, showed improvements in progression-free survival (PFS) in the CodeBreaK 200 trial. However, in October 2023, the FDA rejected its regular approval, keeping its accelerated status pending confirmatory studies.
A 2023 commentary in The Lancet raises concerns about the trial’s statistical analysis and the absolute risks for PFS and overall survival (OS).
Transparency in these studies is essential to properly guide clinical practice.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33
Dec 21, 2024, 13:20
Dec 21, 2024, 13:12